AMIGO2 as a novel indicator of liver metastasis in patients with colorectal cancer

AKIMITSU TANIO¹, HIROAKI SAITO¹,², MASATAKA AMISAKI¹, KAZUSHI HARA¹, KEN SUGEZAWA¹, CHIHIRO UEJIMA¹, YOICHIRO TADA¹, KYOICHI KIHARA¹, MANABU YAMAMOTO¹, KANAE NOSAKA³, RYO SASAKI⁴, MITSUHIKO OSAKI⁴, FUTOSHI OKADA⁴,⁵ and YOSHIYUKI FUJIWARA¹

¹Division of Gastrointestinal and Pediatric Surgery, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8504; ²Department of Surgery, Japanese Red Cross Tottori Hospital, Yonago, Tottori 680-8501; ³Division of Organ Pathology, Faculty of Medicine; ⁴Division of Experimental Pathology, Faculty of Medicine; ⁵Chromosome Engineering Research Center, Tottori University, Yonago, Tottori 683-8503, Japan

Received March 11, 2020; Accepted November 10, 2020

DOI: 10.3892/ol.2021.12539

Abstract. Our previous study showed that adhesion molecule with immunoglobulin like domain 2 (AMIGO2) is a pivotal driver gene of liver metastasis via regulating tumor cell adhesion to liver endothelial cells in mouse models. The aim of the present study was to clarify the role of AMIGO2 in liver metastasis in patients the colorectal cancer (CRC). Two human CRC cell lines, Caco-2 (AMIGO2-low) and HCT116 (AMIGO2-high), were used in this study. AMIGO2-overexpressing Caco-2 and AMIGO2-knockdown HCT116 cells were generated by transfection with an AMIGO2 expression vector or AMIGO2 small interfering RNA, respectively. Cell proliferation, invasion and adhesion to human liver endothelial cells were examined in in vitro studies. Immunohistochemical analysis was also performed to evaluate the association between AMIGO2 expression and liver metastasis in patients with CRC. In vitro studies revealed that cell proliferation, invasion and adhesion to liver endothelial cells were accelerated by upregulation of AMIGO2 expression, but suppressed by downregulation of AMIGO2 expression in human CRC cells. Immunohistochemical analysis using clinical CRC specimens revealed that AMIGO2 expression was associated with the frequency of liver metastasis (P<0.01), but not that of pulmonary metastasis (P=0.611) and peritoneal dissemination (P=0.909). In addition, AMIGO2 expression levels in tumor cells were significantly higher in liver metastatic foci than primary lesions (P=0.012). In conclusion, the present results indicated that AMIGO2 expression may contribute to the formation of liver metastasis in CRC.

Introduction

Colorectal cancer (CRC) is one of the most common malignancies worldwide. Although recent advances in surgical techniques, chemotherapy, and molecular targeted drugs have improved the prognosis of CRC patients, it ranks fourth among all cancer-related deaths worldwide (1). Liver metastasis is the most frequently observed metastasis site and the strongest determinant for prognosis in CRC patients. It occurs in 50% of patients during follow-up for CRC after surgery (2) and is responsible for two-thirds of CRC patient deaths (3). Therefore, it is extremely important to develop new treatments for liver metastasis to improve the prognosis of CRC patients. To this end, it is indispensable to understand the detailed mechanism by which CRC cells metastasize to the liver.

The adhesion molecule with immunoglobulin like domain (AMIGO) family of molecules was identified as novel transmembrane proteins that are involved in neuronal processes by a homophilic binding mechanism (4). It was reported that AMIGO2 inhibits apoptosis and promotes the survival of cerebellar granule neurons (5). Recently, Kanda et al (6) revealed that AMIGO2 functions as a driver gene for liver metastasis in mouse models. In fact, they demonstrated that knockdown of AMIGO2 expression in highly liver metastatic mouse fibrosarcoma cells in vitro and in vivo resulted in the suppression of liver metastasis via attenuation of tumor cell adhesion to hepatic vascular endothelial cells. Conversely, forced expression of AMIGO2 in non-metastatic parental fibrosarcoma cells induced an increase in hepatic vascular endothelial cell adhesion and hepatic metastasis of tumor cells (6). Furthermore, Huo et al (7) recently reported that upregulated AMIGO2 expression became evident as CRC advanced, as detected by transcriptome analysis using The
Cancer Genome Atlas. These results encouraged us to determine the role of AMIGO2 in terms of liver metastasis from CRC. Therefore, the aim of this study was to clarify the role of AMIGO2 in liver metastasis in CRC.

Materials and methods

Cell lines. Caco-2 was purchased from DS Pharma Biomedical (Osaka, Japan) and HCT116 was purchased from the American Type Culture Collection. Caco-2 cells were maintained in EMEM (051-07615; Wako) supplemented with 10% fetal bovine serum (FBS; P30-3306; PAN-Biotech GmbH), 5% non-essential amino acids (139-15651; Wako), penicillin, and streptomycin. Human hepatic sinusoidal endothelial cells (HHSECs) were purchased from ScienCell Research Laboratories, Inc. (cat. no. 5000) and maintained with Endothelial Cell Medium (cat. no. 1001; ScienCell Research Laboratories, Inc.) supplemented with 5% FBS and Endothelial Cell Growth Supplement (cat. no. 1052; ScienCell Research Laboratories, Inc.). Cultures were maintained at 37°C in an atmosphere of 95% air and 5% CO₂.

Western blot analysis. Cells were lysed in protein extraction buffer (28941279; GE Healthcare) containing protease inhibitor (80650123; GE Healthcare) to obtain whole cell lysates. Protein concentrations were determined using a Bradford protein assay. Proteins were separated by 10% SDS-PAGE, and then transferred onto 0.2 µm PVDF membranes (1704156; Bio-Rad). Following incubation in 5% skimmed milk, the membranes were reacted with mouse monoclonal anti-AMIGO2 antibody (1:500, clone G-7, sc-373699; Santa Cruz Biotechnology, Inc.) or with mouse monoclonal anti-β-actin antibody (1:5,000, clone AC-15, A5441; Sigma-Aldrich; Merck KGaA), and then with peroxidase-conjugated sheep monoclonal anti-mouse IgG antibody (1:3,000, NA931; GE Healthcare) in 5% skimmed milk.

Transfection. The pEZ-M02-AMIGO2 expression vector (EX-Mm13004-M02) was purchased from GeneCopoeia. An empty vector used as a control was generated by removing the Amigo2 insert by restriction digest as follows. The pEZ-M02-AMIGO2 plasmid was digested with EcoRI and NotI (R0101S and R0189L, respectively; New England Biolabs). Then 5' overhangs were filled using KOD DNA polymerase (KOD-101; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS, penicillin, and streptomycin. The pEZ-M02 plasmid was digested with EcoRI and NotI (R0101S and R0189L, respectively; New England Biolabs). Then 5' overhangs were filled using KOD DNA polymerase (KOD-101; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS, penicillin, and streptomycin. The plasmids were then incubated with KOD DNA polymerase (KOD-101; Gibco; Thermo Fisher Scientific, Inc.) and two stable clones for OE-AMIGO2 (OE-AMIGO2-Caco-2-1 and OE-AMIGO2-Caco-2-2) and OE-Empty (OE-Empty-Caco-2-1 and OE-Empty-Caco-2-2) were selected in the presence of 750 µg/ml G-418 sulfate (074-05963; Wako). HCT116 cells were transfected with 0.67 µM siRNA targeting AMIGO2 (4392420; Ambion) or with negative control siRNA (4390843; Ambion) using Lipofectamine RNAiMAX (13778100; Invitrogen; Thermo Fisher Scientific, Inc.).

Proliferation assay. The proliferation of CRC cells was evaluated using the CCK-8 assay. Briefly, CRC cells in 200 µl culture medium were seeded in three wells of a 96-well plate at a density of 5,000 cells/well. After 72 h, 10 µl CCK-8 assay solution (347-07621; Dojindo Molecular Technologies, Inc.) was added to each well and the cells were incubated for 60 min at 37°C in an atmosphere of 95% air and 5% CO₂. The absorbance was determined at 450 nm against a reference wavelength of 620 nm using a microplate reader (Infinite F50R; Tecan). The mean value of three wells was used for statistical analysis.

Invasion assay. Caco-2 cells (1x10⁵) were seeded in the inserts of Matrigel-coated invasion chambers (24 wells, 8-µm pore size) filled with serum-free DMEM medium containing 20% FBS in the lower chamber at 37°C in an atmosphere of 95% air and 5% CO₂. After 24 h, non-migrating cells were removed from the top of the filter with a cotton swab. The invading cells at the bottom of the filter were fixed with methanol for 10 min and stained with 0.2% crystal violet and then counted using a microscope (ECLIPSE Ts2; Nikon) in three different visual fields (magnification, x100). The mean value of three different fields was used for statistical analysis.

Adhesion assay. Tumor cell adhesion assays were performed in accordance with previous reports (6,8). Briefly, a 96-well plate (165305; Thermo Fisher Scientific, Inc.) was coated with 1% gelatin (071-06291; Wako) for 16 h. A total of 8x10³ HHSECs were seeded in each well after removal of the gelatin solution. Tumor cells (2x10³) labeled with the PKH67 green fluorescent dye (PKH67GL-1KT; Sigma-Aldrich; Merck KGaA) were then placed onto HHSEC monolayers in the wells and incubated for 30 min. The non-adherent cells were removed by washing with PBS, and the adherent cells were quantified with a fluorescent plate reader (Infinite M200 PRO; Tecan) at an excitation of 485 nm and an emission of 535 nm. The percentage of adherence was calculated as the fluorescence ratio (post-wash fluorescence/pre-wash fluorescence x100).

Patient samples. Immunohistochemical analysis was performed using paraffin-embedded CRC samples from 267 patients with CRC who underwent proctocolectomies at our institution between January 2007 and December 2015. Normal colorectal tissues were available in 119 patients out of 267 patients in which immunohistochemical analysis was performed. Clinicopathological findings were determined by the Japanese Classification of Colorectal Carcinoma (9). None of the patients had received radiotherapy, chemotherapy, or other medical interventions before surgery.

Immunohistochemistry. Tissue samples were fixed in formalin and embedded in paraffin. Serial sections were cut at 4 µm, deparaffinized in xylene, and rehydrated through a graded alcohol series. For retrieval of AMIGO2, the sections were boiled for 20 min in a microwave oven in 10 mM citrate buffer (pH 6.0). The samples were incubated in 3% hydrogen peroxide for 15 min.
peroxidase for 30 min to block endogenous peroxidases and in Block Ace (UK-B80; DS Pharma Biomedical) for 30 min to prevent non-specific antigen binding. The slides were subsequently incubated with primary antibodies (mouse anti-AMIGO2, 1:400; Santa Cruz Biotechnology, Inc.) overnight at 4°C and then incubated with Envision+ Dual Link (K4063; Dako) for 30 min. Staining was visualized with diaminobenzidine (SK-4105; Vector Laboratories) and the sections were counterstained with hematoxylin. The expression of AMIGO2 in CRC cells was evaluated in a blinded manner. In brief, five fields were chosen at random and examined at x400 magnification. The staining intensity on the cell surfaces of CRC cells was scored as 0 (negative), 1 (weak), or 2 (moderate to strong) as previously reported (6). This evaluation was based on the comparison of AMIGO2 expression of lymphocytes in the tissue of CRC since AMIGO2 is expressed in T-cells (10).

Results

AMIGO2 expression in CRC cell lines. We first assessed the expression of AMIGO2 in CRC cell lines by western blotting and found that it was low in Caco-2 and high in HCT116 cells (Fig. 1A). We then determined the efficacy of transfection of EX-Mm13004-M02 and siRNA targeting AMIGO2 in CRC cells. EX-Mm13004-M02 was able to increase AMIGO2 expression in Caco-2 cells (Fig. 1B). Furthermore, siRNA targeting AMIGO2 could efficiently decrease AMIGO2 expression in HCT-116 cells (Fig. 1C).
cells (P<0.001, Fig. 2C and D). Furthermore, the invasive ability of si-AMIGO2-HCT116 cells was significantly less than that of si-NCT-HCT116 cells (P<0.001, Fig. 2E and F). These results indicated that AMIGO2 regulated the proliferation and invasive ability of CRC cells.

**AMIGO2 mediates the adhesion of CRC cells to human hepatic sinusoidal endothelial cells.** We then determined the propensity for CRC cells to adhere to HHSECs. OE-AMIGO2-Caco-2 cells demonstrated significantly increased adhesion to HHSECs, when compared with OE-Empty-Caco-2 cells (P=0.001, Fig. 2G). Furthermore, si-AMIGO2-HCT116 cells demonstrated significantly decreased adhesion to HHSECs, when compared with si-NCT-HCT116 cells (P<0.001, Fig. 2H). These results indicate that AMIGO2 regulates the adhesion of CRC cells to HHSECs.

**AMIGO2 expression in CRC tissue.** We then determined AMIGO2 expression in CRC tissue (Fig. 3). The staining intensity of AMIGO2 on the surfaces of CRC cells was scored as 0 (negative), 1 (weak), or 2 (moderate to strong) as previously reported (6) (Fig. 3A-C). The intensity of AMIGO2 staining was significantly stronger in cancer tissue, when compared with normal tissue (P<0.001, Fig. 3D).

Table 1 shows the association between AMIGO2 expression in CRC tissue and clinicopathological characteristics. AMIGO2 expression was observed more frequently in differentiated tumor than in undifferentiated tumor (P=0.001).

Regarding the association between AMIGO2 expression in CRC tissue and the site of metastasis, including both synchronous and metachronous metastasis, AMIGO2 expression in CRC tissue was significantly related to liver metastasis (P<0.001, Fig. 4A), but not to pulmonary metastasis (P=0.61, Fig. 4B) and peritoneal metastasis (P=0.91, Fig. 4C). Univariate analysis indicated that sex, lymph node metastasis, vascular invasion, and AMIGO2 expression in CRC tissue were factors associated with liver metastasis. Multivariate analysis also revealed that AMIGO2 expression in CRC tissue was an independent predictor of liver metastasis, along with sex, lymph node metastasis, and vascular invasion (Table II). Furthermore, we determined the association between AMIGO2 expression in CRC tissue and metachronous liver metastasis and found that AMIGO2 expression in CRC tissue was also significantly related to metachronous liver metastasis (P<0.001, Fig. 4D). Univariate analysis indicated that lymph node metastasis and AMIGO2 expression in CRC tissue were factors associated with metachronous liver metastasis (Table III). Multivariate analysis also revealed that AMIGO2 expression in CRC tissue...
was an independent predictor of metachronous liver metastasis, along with lymph node metastasis (Table III). Furthermore, AMIGO2 expression in CRC tissue was also significantly related to metachronous liver metastasis in node-negative patients ($P<0.001$, Fig. 4E), but not node-positive patients ($P=0.085$, Fig. 4F).

Finally, we determined AMIGO2 expression in the tissues obtained from liver metastasis of CRC. We compared the intensity of AMIGO2 between a primary CRC lesion (Fig. 5A) and a matched liver metastatic lesion (Fig. 5B). The intensity of AMIGO2 staining was significantly stronger in the tissue obtained from the liver metastasis of CRC, when compared with the primary lesion ($n=21$, $P=0.012$, Fig. 5C). With regard to the association between AMIGO2 expression in CRC tissue and prognosis of CRC patients, the prognosis of patients with high AMIGO2 mRNA expression in CRC tissue was significantly worse than that of patients with low AMIGO2 mRNA expression in CRC tissue ($P=0.013$, Fig. 5D).

### Table I. Association between AMIGO2 expression and clinicopathological features.

| Variables                     | 0 (n=82) (%) | 1 (n=126) (%) | 2 (n=59) (%) | P-value |
|-------------------------------|-------------|---------------|-------------|---------|
| Age, years                    |             |               |             |         |
| <70 (n=127)                   | 35 (27.6)   | 68 (53.5)     | 24 (18.9)   | 0.137   |
| ≥70 (n=140)                   | 47 (33.6)   | 58 (41.4)     | 35 (25.0)   |         |
| Sex                           |             |               |             |         |
| Male (n=146)                  | 48 (32.9)   | 64 (43.8)     | 34 (23.3)   | 0.480   |
| Female (n=121)                | 34 (28.1)   | 62 (51.2)     | 25 (20.7)   |         |
| Tumor location                |             |               |             |         |
| Colon (n=190)                 | 62 (32.6)   | 84 (44.2)     | 44 (23.2)   | 0.306   |
| Rectum (n=77)                 | 20 (26.0)   | 42 (54.5)     | 15 (19.5)   |         |
| Tumor size, cm                |             |               |             |         |
| <4.0 (n=103)                  | 34 (33.0)   | 45 (43.7)     | 24 (23.3)   | 0.659   |
| ≥4.0 (n=164)                  | 48 (29.3)   | 81 (49.4)     | 35 (21.3)   |         |
| Histology<sup>a</sup>         |             |               |             |         |
| Differentiated (n=235)        | 63 (26.8)   | 115 (48.9)    | 57 (42.3)   | 0.001   |
| Undifferentiated (n=32)       | 19 (59.4)   | 11 (34.4)     | 2 (6.2)     |         |
| Depth of invasion<sup>b</sup> |             |               |             |         |
| T1/T2 (n=19)                  | 5 (26.3)    | 9 (47.4)      | 5 (26.3)    | 0.863   |
| T3/T4 (n=248)                 | 77 (31.0)   | 117 (47.2)    | 54 (21.8)   |         |
| Lymph node metastasis         |             |               |             |         |
| Absent (n=139)                | 46 (33.1)   | 67 (48.2)     | 26 (18.7)   | 0.348   |
| Present (n=128)               | 36 (28.1)   | 59 (46.1)     | 33 (25.8)   |         |
| Lymphatic invasion<sup>c</sup>|             |               |             |         |
| ly0/1 (n=105)                 | 32 (30.5)   | 52 (49.5)     | 21 (20.0)   | 0.761   |
| ly2/3 (n=162)                 | 50 (30.9)   | 74 (45.7)     | 38 (23.4)   |         |
| Vascular invasion<sup>d</sup> |             |               |             |         |
| v0/1 (n=159)                  | 45 (28.3)   | 81 (50.9)     | 33 (20.8)   | 0.327   |
| v2/3 (n=108)                  | 37 (34.2)   | 45 (41.7)     | 26 (24.1)   |         |

<sup>a</sup>Histology: Differentiated, well or moderately differentiated adenocarcinoma; Undifferentiated, poorly differentiated adenocarcinoma, signet ring cell carcinoma or mucinous carcinoma.  
<sup>b</sup>T1, tumor invasion of the lamina propria or submucosa; T2, tumor invasion of the muscularis propria; T3, tumor invasion of the subserosa or within adventitia; T4, tumor penetration of the serosa or tumor invasion of adjacent organs.  
<sup>c</sup>Lymphatic invasion: ly0‑ly3, grade of lymphatic invasion.  
<sup>d</sup>Vascular invasion: v0‑v3, grade of vascular invasion. $\chi^2$ test was used for the statistical analysis. AMIGO2, adhesion molecule with Ig like domain 2.

Discussion

Metastasis is a multi-stage process that is collectively termed the invasion-metastasis cascade, in which cancer cells: i) Proliferate and locally invade through the surrounding extracellular matrix and stromal cell layers; ii) intravasate into the lumina of blood vessels; iii) survive the rigors of transport through the vasculature; iv) arrest at distant organ sites; v) extravasate into the parenchyma of distant tissues; vi) initially survive in these foreign microenvironments to form micrometastases; and vii) re-initiate their proliferative
programs at metastatic sites, thereby generating macroscopic, clinically detectable neoplastic growths. These processes are orchestrated by molecular pathways operating within carcinoma cells. Among these seven processes, we first demonstrated...
that AMIGO2 was closely related to the proliferation and invasion of CRC cells in the current study. With regards to the function of AMIGO2, it was reported to be involved in cell survival and angiogenesis via AKT signaling (11). However, it remains unclear whether AMIGO2 is involved in cell survival and angiogenesis via AKT signaling in CRC. It has recently been reported that AMIGO2 is upregulated in malignant melanoma, and that AMIGO2 and its interactor tyrosine-protein kinase-like 7 (PTK7) regulate the proliferation and survival of tumor cells in this disease (12). PTK7 is also known as colon carcinoma kinase 4. This gene is thought to be expressed in CRC but not in normal colon, and therefore may be involved in CRC progression (13-15). Although there is no report regarding the correlation between AMIGO2 and PTK7 in CRC thus far, it is likely that AMIGO2 regulates the proliferation of CRC cells through PTK7. With regards to invasion, Sonzogni et al (16) recently reported AMIGO2 as a new mediator of invasion in breast cancer. In the current study, we demonstrated that AMIGO2 knockdown in HCT116 cells suppressed invasive behavior. Furthermore, its overexpression in Caco-2 cells was sufficient to induce invasion, demonstrating that AMIGO2 also has important roles in the invasiveness of CRC cells.

Our study also demonstrated that AMIGO2 was closely associated with the adhesion of CRC cells to HHSECs. Furthermore, AMIGO2 expression on cancer cells in CRC tissue was related to increased frequency of liver metastasis. Of importance is that AMIGO2 expression on cancer cells in CRC tissue was not related to lung and peritoneal metastasis. In this regard, Kanda et al (6) demonstrated that the adhesion of LV12 cells, an isolated subline of QRsP-11 fibrosarcoma cells with high liver-metastatic properties, to liver endothelial cells was

### Table II. Univariate and multivariate analyses of risk factors for liver metastases in patients with colorectal cancer.

| Variables                                      | Univariate analysis | Multivariate analysis |
|------------------------------------------------|---------------------|-----------------------|
|                                                 | P-value  | HR       | 95% CI               | P-value  | HR       | 95% CI               |
| Age (<70 vs. ≥70 years)                        | 0.459    | 1.234    | 0.707-2.153          | 0.012    | 2.260    | 1.200-4.254          |
| Sex (female vs. male)                          | 0.025    | 1.941    | 1.085-3.473          | 0.012    | 2.260    | 1.200-4.254          |
| Tumor location (colon vs. rectum)              | 0.992    | 1.003    | 0.543-1.854          | 0.014    | 2.165    | 1.170-4.006          |
| Tumor size (<4.0 vs. ≥4.0 cm)                  | 0.113    | 1.618    | 0.892-2.934          | 0.014    | 2.165    | 1.170-4.006          |
| Histology (differentiated vs. undifferentiated)| 0.210    | 0.528    | 0.195-1.433          | 0.010    | 2.220    | 1.206-4.088          |
| Depth of invasion (pT1/2 vs. pT3/4)             | 0.155    | 2.957    | 0.665-13.151         | 0.010    | 2.220    | 1.206-4.088          |
| Lymph node metastasis (absent vs. present)     | 0.004    | 2.340    | 1.318-4.155          | 0.010    | 2.220    | 1.206-4.088          |
| Lymphatic invasion (ly0/1 vs. ly2/3)            | 0.252    | 1.407    | 0.785-2.522          | 0.010    | 2.220    | 1.206-4.088          |
| Vascular invasion (v0/1 vs. v2/3)               | 0.008    | 2.150    | 1.223-3.778          | <0.001   | 2.585    | 1.677-3.985          |
| AMIGO2 (0 vs. 1 vs. 2)                         | <0.001   | 2.511    | 1.651-3.817          | <0.001   | 2.585    | 1.677-3.985          |

HR, hazard ratio; CI, confidence interval; AMIGO2, adhesion molecule with Ig like domain 2. Logistic regression analysis was used for the statistical analysis.

### Table III. Univariate and multivariate analyses of risk factors for metachronous liver metastases in patients with colorectal cancer.

| Variables                                      | Univariate analysis | Multivariate analysis |
|------------------------------------------------|---------------------|-----------------------|
|                                                 | P-value  | HR       | 95% CI               | P-value  | HR       | 95% CI               |
| Age (<70 vs. ≥70 years)                        | 0.432    | 1.363    | 0.629-2.957          | 0.040    | 2.357    | 1.042-5.332          |
| Sex (female vs. male)                          | 0.449    | 1.344    | 0.625-2.888          | 0.040    | 2.357    | 1.042-5.332          |
| Tumor location (colon vs. rectum)              | 0.984    | 1.009    | 0.438-2.321          | 0.040    | 2.357    | 1.042-5.332          |
| Tumor size (<4.0 vs. ≥4.0 cm)                  | 0.341    | 1.477    | 0.661-3.300          | 0.040    | 2.357    | 1.042-5.332          |
| Histology (differentiated vs. undifferentiated)| 0.564    | 0.690    | 0.196-2.429          | 0.040    | 2.357    | 1.042-5.332          |
| Depth of invasion (pT1/2 vs. pT3/4)             | 0.311    | 2.772    | 0.356-21.603         | 0.040    | 2.357    | 1.042-5.332          |
| Lymph node metastasis (absent vs. present)     | 0.027    | 2.431    | 1.107-5.341          | 0.040    | 2.357    | 1.042-5.332          |
| Lymphatic invasion (ly0/1 vs. ly2/3)            | 0.105    | 2.022    | 0.863-4.741          | 0.040    | 2.357    | 1.042-5.332          |
| Vascular invasion (v0/1 vs. v2/3)               | 0.318    | 1.475    | 0.687-3.167          | <0.001   | 3.151    | 1.729-5.742          |
| AMIGO2 (0 vs. 1 vs. 2)                         | <0.001   | 3.175    | 1.785-5.733          | <0.001   | 3.151    | 1.729-5.742          |

HR, hazard ratio; CI, confidence interval; AMIGO2, adhesion molecule with Ig like domain 2. Logistic regression analysis was used for the statistical analysis.
significantly higher than that of QRsP-11 cells, whereas adhesion to lung endothelial cells (LE-1) was similar in both cell lines. They also showed that the incidence of liver metastasis was higher following intravenous injection of LV12 cells than following injection of QRsP-11 cells. However, there was no difference in the incidence of lung metastasis between the two cell lines, suggesting that LV12 cells have a higher capacity to colonize the liver. Finally, they revealed that AMIGO2, which was overexpressed in LV12 cells, functioned as a driver gene for liver metastasis. We also found that AMIGO2 was more strongly expressed on the surfaces of cells in liver metastasis lesions compared with its expression in the primary lesions of human CRC in this study. These results may verify the involvement of AMIGO2 expression in the formation of liver metastases in clinical samples. However, the precise mechanisms by which selective and firm adhesion to liver endothelial cells, but not lung endothelial cells, can be brought about by AMIGO2 expression remain unclear. One possible mechanism to explain the AMIGO2-mediated cell adhesion is homophilic or heterophilic binding among the three homologous proteins that comprise the AMIGO family, i.e., AMIGO1, AMIGO2, and AMIGO3 (4). Regarding this, Kanda et al (6) showed that all these AMIGO family molecules are expressed on liver endothelial cells; however, none of these AMIGO molecules are expressed on LE-1 lung endothelial cells. Further experiments are required to resolve these mechanisms.

Of critical importance is the question of whether our results will prove useful to the diagnosis and treatment of CRC patients. With respect to the clinical usefulness of AMIGO2 in CRC, this study revealed that AMIGO2 was an independent predictive factor of metachronous liver metastasis. The resection of liver metastasis improves the prognosis of CRC patients. A recent study demonstrated more than 60 months of median overall survival in CRC patients with up to four liver metastases who underwent surgery combined with perioperative FOLFOX4. It is likely that early detection of metachronous liver metastasis increases the resection rates of liver metastasis, improving the prognosis of CRC patients. Our results also demonstrated that lymph node metastasis was a useful predictive indicator of metachronous liver metastasis. Of importance is that AMIGO2 expression was a useful predictive indicator of metachronous liver metastasis even in node-negative CRC patients. Therefore, evaluation of AMIGO2 in resected specimens by immunohistochemistry might be useful in detecting node-negative CRC patients who have a high possibility of metachronous liver metastasis and need intensive follow-up and adjuvant chemotherapy after surgery, which may improve the prognosis of CRC patients.

Regarding treatment, a recent study demonstrated that AMIGO2 was upregulated in melanoma cells and tissues compared with human melanocytes and nevi, and AMIGO2 silencing in melanoma cells induces G1/S arrest followed by
apoptosis. Furthermore, a BET inhibitor was shown to be able to silence AMIGO2 expression (12). Considering the multifunctional aspects of AMIGO2 shown in the current study, it is likely that BET inhibition may be useful in the treatment of CRC patients with high AMIGO2 expression. Considering the close association between AMIGO2 expression on CRC cells and liver metastasis observed in the current study, treatment directly targeting AMIGO2 might be effective in preventing liver metastasis in CRC, eventually improving the prognosis of CRC patients.

In conclusion, AMIGO2 contributes to the formation of liver metastasis by regulating CRC cell adhesion to human hepatic sinusoidal endothelial cells, as well as the proliferation and invasion of CRC cells. Treatments that target AMIGO2 could therefore provide a novel form of CRC treatment.

Acknowledgements

The authors would like to thank Dr H. Nikki March for editing a draft of this manuscript.

Funding

This work was supported by grants from Takeda Pharmaceutical Company Limited.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Authors' contributions

HS, AT, MA, KN, MO, FO and YF designed the study and wrote the paper. AT and RS carried out experiments. AT, KH, KS, CU, YT, KK and MY analyzed clinical data of patients with colorectal cancer. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The study protocol was approved by the Institutional Review Board at Tottori University Hospital (approval number: 1705A039). All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Written informed consent to be obtained (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Written informed consent to be obtained in the study was obtained from all patients.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. Matsuoka H, Morise Z, Tanaka C, Hayashi T, Ikeda Y, Maeda K, Masumori K, Koida Y, Katsuno H, Tanahashi Y, et al.: Repeat hepatectomy with systemic chemotherapy might improve survival of recurrent liver metastasis from colorectal cancer: a retrospective observational study. World J Surg Oncol 17: 33, 2019.
3. Abdalla EK, Adam R, Bilchik AJ, Jaecck D, Vauthay JN and Mahvi D: Improving resectability of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol 13: 1271-1280, 2006.
4. Kuja-Panula J, Kiltomaki M, Yamashiro T, Rouhiainen A and Rauvala H: AMIGO, a transmembrane protein implicated in axon tract development, defines a novel protein family with leucine-rich repeats. J Cell Biol 160: 963-973, 2003.
5. Ono T, Sekino-Suzuki N, Kikkawa Y, Yonekawa H and Kawashima S: Alvin, a novel neuronal activity-dependent gene, inhibits apoptosis and promotes survival of cerebellar granule neuron, J Neurosci 23: 5887-5896, 2003.
6. Kanda Y, Osaki M, Onuma K, Sonoda A, Kobayashi M, hammera J, Nicolson GL, Ochiya T and Okada F: AMIGO2-upregulation in tumour cells facilitates their attachment to liver endothelial cells resulting in liver metastases. Sci Rep 7: 43567, 2017.
7. Hino T, Canepa R, Sura A, Modave F and Gong Y: Colorectal cancer stages transcriptome analysis. PLoS One 12: e0188697, 2017.
8. Onuma K, Suenaga Y, Sakaki R, Yoshitome S, Sato Y, Ogawara S, Suzuki S, Kuramitsu Y, Yokoyama H, Murakami A, et al.: Development of a quantitative bioassay to assess preventive compounds against inflammation-based carcinogenesis. Nitric Oxide 25: 183-194, 2011.
9. Japanese Society for Cancer of the Colon and Rectum: Japanese classification of colorectal carcinoma, 2nd English edition. Kanehara & Co., Ltd, 2009.
10. Li Z, Khan MM, Kuja-Panula J, Wang H, Chen Y, Guo D, Chen ZJ, Lahesmaa R, Rauvala H and Tian L: AMIGO2 modulates T cell functions and its deficiency in mice ameliorates experimental autoimmune encephalomyelitis. Brain Behav Immun 62: 110-123, 2017.
11. Park H, Lee S, Shrestha P, Kim J, Park JA, Ko Y, Ban YH, Park DY, Ha SJ, Koh GY, et al.: AMIGO2, a novel membrane anchor of PDK1, controls cell survival and angiogenesis via Akt activation. J Cell Biol 211: 619-637, 2015.
12. Fontanals-Cirera B, Hasson D, Vandabasso C, Di Micco R, Agrawal P, Chowdhury A, Gantz M, de Pablos-Aragoneses A, Morgenstern A, Wu P, et al.: Harnessing BET inhibitor sensitivity reveals AMIGO2 as a melanoma survival gene. Mol Cell 68: 731-744.e4, 2017.
13. Saha S, Sparks AB, Rago C, Akmaev V, Wang CJ, Vogelstein B, Kinzler KW and Velculescu VE: Using the transcriptome to annotate the genome. Nat Biotechnol 20: 508-512, 2002.
14. Tian X, Yan L, Zhang D, Guan X, Dong B, Zhao M and Hao C: PTK7 overexpression in colorectal tumors: Clinicopathological correlation and prognosis relevance. Onco Targets Ther 12: 871-885, 2019.
15. Lhoumeau AC, Martinez S, Hofer JM, Menges G, Castellano R, Gourdard A, Doremus M, Poizat F, Lelong B, de Chaisemartin C, et al.: Overexpression of the promigratory and prometastatic PTK7 receptor is associated with an adverse clinical outcome in colorectal cancer. J Pathology 244: 903-912, 2019.